BNLMs tended to present at a more advanced stage, with thicker primary tumors, but had a metastatic pattern comparable to and was not more aggressive in behavior than other types of melanoma. The authors concluded that BNLMs should be treated in the same way as any other melanoma variants based on clinical staging and pathologic prognostic indices.
Iman Osman, M. Berwick, InterMEL, Li Luo, Judy R. Rees, Sheri L. Holmen, Jennifer S. Ko, Kathleen Conway, Pauline Funchain, M.S. Ernstoff, Adam Z. Reynolds, Nancy E. Thomas, Marcus Bosenberg, Venkatraman Seshan, Arshi Arora, Tawny W. Boyce, Peter Ngo, Matthew Schwartz, C.L. Thompson, I. Gorlov, Shenying Fang, P.F. Kuan, Graham J. Mann, Irene Orlow, Eva Hernando, Eduardo Nagore, James S. Wilmott, Richard A Scolyer, Paul N. Bogner, Klaus J. Busam, Tim K. Lee, Meg R. Gerstenblith, Bonnie Gould Rothberg, Colin B. Begg, Anne Ε. Cust, Charles L. Wiggins, Elise K. Brunsgaard, S.N. Edmiston, Yvonne M. Saenger, David W. Ollila, Cecilia Lezcano, Christopher I. Amos, Ronglai Shen, Jeffrey E. Lee, P.B. Googe
Li Luo, Ronglai Shen, Arshi Arora, Irene Orlow, Klaus J. Busam, Cecilia Lezcano, Tim K. Lee, Eva Hernando, Ivan Gorlov, Christopher I. Amos, Marc S. Ernstoff, Venkatraman Seshan, Anne Ε. Cust, James S. Wilmott, Richard A Scolyer, Graham J. Mann, Eduardo Nagore, Pauline Funchain, Jennifer S. Ko, Peter Ngo, Sharon N. Edmiston, Kathleen Conway, Paul B. Googe, David W. Ollila,
Discussion(0)
No comments yet. Be the first to comment.